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Summary
Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative had developed two sets of responder criteria to
present the results of changes after treatment in three symptomatic domains (pain, function, and patient’s global assessment) as a single
variable for clinical trials (1). For each domain, a response was defined by both a relative and an absolute change, with different cut-offs with
regard to the drug, the route of administration and the OA localization.
Objective: To propose a simplified set of responder criteria with a similar cut-off, whatever the drug, the route or the OA localization.
Methods: Data driven approach:
(1) Two databases were considered
+ The ‘elaboration’ database with which the formal OARSI sets of responder criteria were elaborated and
+ The ‘revisit’ database.
(2) Six different scenarios were evaluated:
+ The two formal OARSI sets of criteria
+ Four proposed scenarios of simplified sets of criteria
Data from clinical randomized blinded placebo controlled trials were used to evaluate the performances of the two formal scenarios with two
different databases (‘elaboration’ versus ‘revisit’) and those of the four proposed simplified scenarios within the ‘revisit’ database. The
placebo effect, active effect, treatment effect, and the required sample arm size to obtain the placebo effect and the active treatment effect
observed were the performances evaluated for each of the six scenarios. Experts’ opinion approach: Results were discussed among the
participants of the OMERACT VI meeting, who voted to select the definite OMERACT-OARSI set of criteria (one of the six evaluated
scenarios).
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Results: Data driven approach: Fourteen trials totaling 1886 OA patients and fifteen studies involving 8164 OA patients were evaluated in the
‘elaboration’ and the ‘revisit’ databases respectively.
The variability of the performances observed in the ‘revisit’ database when using the different simplified scenarios was similar to that
observed between the two databases (‘elaboration’ versus ‘revisit’) when using the formal scenarios. The treatment effect and the required
sample arm size were similar for each set of criteria. Experts’ opinion approach: According to the experts, these two previous performances
were the most important of an optimal set of responder criteria. They chose the set of criteria considering both pain and function as evaluation
domain and requiring an absolute change and a relative change from baseline to define a response, with similar cut-offs whatever the drug,
the route of administration or the OA localization.
Conclusion: This data driven and experts’ opinion approach is the basis for proposing an optimal simplified set of responder criteria for OA
clinical trials. Other studies, using other sets of OA patients, are required in order to further validate this proposed OMERACT – OARSI set
of criteria.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
The Osteoarthritis Research Society International (OARSI)
Standing Committee for Clinical Trials Response Criteria
Initiative and the Outcome Measures in Rheumatology
(OMERACT) committee, in concert with the international
rheumatology community, has led to the development of a
uniform core set of outcome measures for osteoarthritis
(OA)1–4. One of the objectives was to propose a set of
criteria for measurement based on multiple domains to
present the results of changes after treatment in sympto-
matic parameters as a single variable for clinical trials. The
symptomatic variables selected by both the OMERACT
and OARSI societies were: pain, functional impairment and
patient’s global assessment.
Based on data from clinical trials, two sets of responder
criteria (formal OARSI criteria) that can categorize an
individual’s response to treatment in a clinical trial have
been developed5 (Fig. 1).
The main characteristics of the proposed sets of criteria
were the following:
+ They covered three domains: pain, function and
patient’s global assessment.
+ For each of these domains, a response was defined by
both a relative and an absolute change.
+ The cut-offs that defined a relevant change differed
with regard to:
+ OA localization (e.g. hip vs knee),
+ evaluated study drug (e.g. NSAIDs vs specific
anti-OA drug),
+ route of administration (e.g. per os vs intra-
articular),
+ specific domain (pain, function, patient’s global
assessment).
The choice of the different cut-offs for the formal OARSI
set of criteria was based on statistical analysis for optimiz-
ation of the discriminant capacity. The preliminary attempts
at uniform cut-off of all subsets showed a lesser placebo
and active treatment effect of the set of criteria considered
relevant by the members of the steering committee.
The main objective of this study was to evaluate the
performances of the two previous formal OARSI sets of
criteria and the performances of the modified ones, pro-
posed by the scientific OMERACT committee. The aim of
the proposed modifications was to simplify the presentation
of the set of criteria, by evaluating different scenarios
whatever the OA localization, whatever the evaluated drug,
whatever the route of administration, and with similar
cut-offs for the different domains.
Methods
PROPOSED SET OF CRITERIA
Six different scenarios were evaluated. The first two
scenarios were the two propositions (A and B) of the formal
OARSI set of criteria5 (Fig. 1). The four other scenarios
(scenarios C to F) were proposed by the OMERACT
scientific committee. Their main characteristic was that
they used a uniform cut-off whatever the OA localization,
whatever the study drug and whatever the route of
administration, unlike the formal OARSI set of criteria
(Fig. 2). Scenarios A, C and E considered pain at the first
responder step (high improvement), and scenarios B, D
and F considered pain or function (Fig. 3). Scenarios C and
D, as the formal OARSI set of criteria did, considered
relative change (percentage of change during the study)
and absolute change (absolute change during the study) in
the variable to define a response, whereas scenarios E and
F considered only relative change to define such response.
The study approach was both data driven and used an
experts’ opinion approach.
DATA DRIVEN APPROACH
Two databases from clinical randomized placebo con-
trolled trials were used:
+ The initial one used to elaborate the formal set of
criteria, known here as the ‘elaboration database’.
+ The second one is labeled the ‘revisit database’. Drug
companies who had conducted positive randomized
placebo controlled trials in OA of a minimum 4-week
duration were invited to revisit their database. The
definition of ‘positive’ was based on a p value <0.05 for
the a priori chosen primary criterion of the trial. Only
the intention-to-treat analysis trials using the Last
Observation Carried Forward technique were used.
The participating drug companies were invited to
provide anonymous information: OA localization, route
of administration, characteristics of the study drug
(analgesic, NSAID, Specific OA drug), study duration,
number of patients in the placebo group and in the
active treatment group, tools used to evaluate pain
(e.g. pain VAS, Likert scale, WOMAC pain subscale),
function (e.g. WOMAC function subscale) and patient’s
global assessment (e.g. VAS, Likert scale)6, and time
of collection of these different tools. Because of confi-
dentiality, no demographic data, such as age, gender,
body mass index, nor baseline values were asked
to the drug companies. The drug was not identified
by name, but only by class of agent (e.g. NSAIDs,
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Subgroup 
High improvement in pain Moderate improvement in
Pain Function
Relative
change*
Absolute
change**
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Knee, oral NSAIDs 45 20 15 10 30 15 35 10
Knee, oral specific 
drug
55 30 35 10 15 20 15 15
The 3 above groups 
together
55 30 35 15 15 20 15 15
Knee, intra-articular 
specific drug  
40 30 35 15 35 10 30 10
Proposition A Optimal cut-offs to be applied for the OARSI Responder Criteria
Subgroup 
High improvement in
 Pain Function 
Moderate improvement in 
Pain Function Global assessment
Relative 
change* 
Absolute 
change**
Relative 
change 
Absolute 
change 
Relative 
change 
Absolute 
change 
Relative 
change 
Absolute 
change 
Relative 
change 
Absolute
change
Hip, NSAIDs  50 30 50 20 25 15 20 10 20 10
Knee, oral 
NSAIDs 50 20 60 20 30 15 20 20 25 10
Knee, oral 
specific drug 
55 30 50 20 30 20 20 20 20 15
The 3 above 
groups together  55 30 50 20 30 15 20 20 20 15
Knee, intra-
articular specific 
drug  
50 30 60 20 20 20 30 10 30 10
Proposition B Optimal cut-offs to be applied for the OARSI Responder Criteria
* Relative change: percentage of change during the study (final minus baseline over baseline  100) 
** Absolute change: absolute change during the study (final minus baseline on a 0-100 interval scale) 
High improvement in pain 
Moderate improvement in at least 2 of the 3 following:
•  Pain 
•  Function 
•  Patient ’s global assessment 

Yes 

Response 

No 

No response

Yes 

Response

No 

High improvement in pain or function
Moderate improvement in at least 2 of the 3 following:
•  Pain 
•  Function 
•  Patient ’s global assessment 

Yes 

Response

No 

No response

Yes 

Response

No 

H
Fig. 1. OARSI Formal set of criteria: Scenarios A and B.
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Fig. 2. Evaluated simplified sets of criteria: Scenarios C to F.
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systemic specific drug, intra-articular specific drug). For
each trial and each scenario, a drug company provided
the number of patients and the number of responders
in each treatment arm. With this information, sensitivity
(percentage of patients receiving an active drug
labeled as responders according to the proposed set of
criteria) and specificity (percentage of patients receiv-
ing the placebo treatment labeled as non-responder
according to the proposed set of criteria) could be
calculated for each trial and for each drug class and
joint location of interest.
The first step of the data driven approach consisted in the
evaluation of the performances of the two formal scenarios
(scenario A and B), using the two databases, for each
category of trial studied during the elaboration step (i.e.
hip OA–NSAIDs trials, knee OA–NSAIDs trials, knee
OA–systemic specific drug trials and knee OA–intra-
articular specific drug trials). In other words, we compared
the following performances in the ‘elaboration’ and in the
‘revisit’ database: placebo effect (percentage of responders
in the placebo group), active effect (percentage of respond-
ers in the active treatment group), treatment effect (per-
centage of patients improved in the active treatment group
minus the percentage of patients improved in the placebo
group) and the sample arm size needed to obtain the
observed placebo and active treatment effects (=0.05 and
=0.20, two tailed test).
The second step consisted in the evaluation of the above
performances between the six scenarios within the revisit
database. For each drug and for each OA localization,
the number of patients in the active treatment group and in
the placebo group, the placebo effect, the active effect, the
treatment effect and the sample arm size needed to obtain
the observed placebo effect and the active treatment effect
were calculated. These evaluations were also calculated
whatever the localization and/or whatever the treatment.
Moreover, since criteria sets almost always performed
optimistically well when evaluated with the same database
which was used to hunt for ‘optimum’ scenario, we com-
pared the performances of the scenarios C, D, E and F in
the elaboration database to the performances of the
scenarios A and B in the revisit database.
Experts’ opinion approach: Based on the data observed
and after discussion among the OMERACT VI meeting
participants, a vote was conducted to select the definite
OMERACT-OARSI set of criteria (one of the six evaluated
scenarios).
Lastly, the sensitivity and the specificity of the selected
scenario has been evaluated in the “elaboration” database
(knee OA–NSAIDs trials, hip OA–NSAIDs trials). The
sensitivity was defined by the percentage of NSAIDs-OA
patients meeting the OMERACT-OARSI criteria. The
1-specificity was defined by the percentage of placebo-OA
patients meeting the OMERACT-OARSI criteria.
Results
PATIENTS AND STUDIES
In the elaboration database, fourteen trials totaling 1886
patients were evaluated (see Ref. 5 for details). The
majority of the information was on NSAIDs for knee and hip.
In the revisit database, fifteen studies involving 8164 OA
patients were screened (Fig. 3). None of the studies was
excluded. A prospective randomized controlled study in
which the control group was receiving the usual therapeutic
care without true placebo (vs. an intra-articular OA drug)
was included in the revisit database. There were no trials
6FUHHQHG VWXGLHV  
 SDWLHQWV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 
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 
  SDWLHQWV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+LS 2$
16$,'V
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Q  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Fig. 3. Flow diagram for numbers of studies and patients.
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available to examine analgesics in OA. The majority of the
studies concerned NSAIDs in hip and knee OA (10 of 15).
The characteristics of study designs are summarized in
Table I. The data concerned 647 patients in systemic
specific OA drug trials, 606 patients in intra-articular (IA)
specific OA drug trials and 6911 patients in NSAIDs trials.
For NSAIDs studies, whatever the OA localization, 5557
patients received the active treatment, and 1354 the pla-
cebo. Two studies involving hip and/or knee OA without
indication of the localization were included only in the
“whatever the localization” calculation. To assess pain and
functional disability, two tools were most often used:
The visual analog scale (VAS) and the Western Ontario
McMaster Universities Osteoarthritis (WOMAC) index. For
global patient’s assessment, the VAS and the Likert scale
were mostly used.
The knee was the only OA localization of the five specific
OA drug studies (systemic and intra-articular), while
NSAIDs trials were conducted in both knee and hip OA.
DATA DRIVEN APPROACH RESULTS
Formal set of criteria performances: comparison
between elaboration database and revisit database
Results concerning the placebo and the treatment effects
are summarized in Table II. For both the propositions A and
B, the variability in the placebo and the active treatment
effects were quite high (from 4% to 21% in the placebo
group and from 7% to 34% in the active treatment group).
Based on the observed results (placebo effect and active
treatment effect) in the elaboration database, the calcu-
lation of the sample size required in future NSAIDs trials in
knee OA was 67 patients per arm with scenario A and 66
with scenario B.
Performances of the 6 scenarios in the revisit
database according to drug class, route of
administration and OA localization
The results of the evaluated performance for each
scenario are summarized in Table III. The highest active
treatment effect and placebo effect were observed when
using scenario F, whatever the drug class and whatever the
localization.
NSAIDs in Knee OA. The highest active treatment effect
was observed when using scenario F (66.4%), and at
variance, the lowest placebo effect was observed when
using scenario B (39.1%). The treatment effect was similar
whatever the scenario (19.8%, 19.3%, 19.8%, 19.5%,
19.9% and 19.8% for scenarios A, B, C, D, E and F
respectively). The sample sizes “required” in future NSAID
knee trials using the “revisit” data were 99 patients per arm,
scenario A and 105 per arm, scenario B. Using the simpli-
fied scenarios, the sample sizes “required” were 98 per
arm, scenario C, 101 per arm, scenario D, 97 per arm,
scenario E and 98 per arm, scenario F.
NSAIDs in Hip OA. The highest active treatment effect
was observed when using scenario F (60.8%), and at
variance the lowest placebo effect was observed when
using scenario A (28.9%). As observed in knee OA, the
treatment effect was similar whatever the scenario (24.7%,
26.5%, 25.9%, 25.7%, 25.3% and 25.3% for scenarios A,
B, C, D, E and F respectively). The sample sizes ‘required’
in future NSAID hip trials using the ‘revisit’ data were 62
patients per arm, scenario A and 55 per arm, scenario B.
Using the simplified scenarios, the sample sizes ‘required’
were 58 per arm, scenario C, 59 per arm, scenario D and
61 per arm, scenario E and scenario F.
Systemic Specific OA drug in Knee OA. The highest
active treatment effect was observed when using scenario
F (49.4%), and the lowest placebo effect was observed
when using scenario B (29.0%). Scenarios A and B showed
the highest treatment effect (6.9% and 6.8% respectively)
and the lowest sample size “required” for future systemic
specific OA drug trials in knee OA (743 and 745 patients
per arm respectively, versus 1167, 1095, 4979 and 3824
patients per arm for scenarios C, D, E and F).
Intra-articular specific OA drug in Knee OA. The highest
active treatment effect was observed when using scenario
F (72.9%), and the lowest placebo effect was observed
when using scenario B (34.6%). The highest treatment
Table I
Characteristics of the 15 studies included in the ‘revisit’ database* according to agent class
Characteristics Drug class
NSAIDs Systemic specific
OA drug
Intra articular specific
OA drug
Number of studies 10 3 2
Number of patients Active drug group 5557 316 303
Placebo or control group 1354 331 303
Study duration (mean +/- sd; weeks) 9.3±3.8 105.3±87.7 33±9.9
Pain evaluation WOMAC 40% 100% 50%
VAS 60% 0 50%
Others 0 0 0
Function evaluation WOMAC 100% 100% 50%
VAS 0 0 50%
Other 0 0 0
Global assessment evaluation Likert 40% 33% 0
VAS 30% 66% 50%
Other 30% 50%
Time of collection of the outcome variables Final and baseline 100% 100% 100%
Only final visit 0 0 0
*‘Revisit’ data base is the one that permitted to revisit the formal sets of responder criteria and to evaluate the simplified sets of responder
criteria.
WOMAC: Western Ontario McMaster Universities Osteoarthritis index; VAS: Visual Analogic Scale.
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Table II
Performances observed with the formal sets of criteria, propositions A and B* (e.g. scenarios A and B) in the ‘elaboration’ and in the ‘revisit’ databases**: placebo effect, active treatment effect,
treatment effect, and variability between the two databases)
Formal OARSI set of criteria
Proposition A (pain)* Proposition B (pain or function)*
Trials Elaboration** Revisit** (Revisit-Elaboration) Elaboration** Revisit** (Revisit-Elaboration)
Knee OA Systemic Specific OA drug Placebo effect 51% 31% −20 50% 29% −21
Active treatment effect 62% 38% −24 61% 36% −25
Treatment effect 11% 7% −4 11% 7% −4
Knee OA IA Specific OA drug Placebo effect 47% 35% −12 47% 35% −12
Active treatment effect 92% 58% −34 91% 57% −34
Treatment effect 45% 23% −22 44% 22% −22
Hip OA NSAIDs Placebo effect 33% 29% −4 39% 32% −7
Active treatment effect 62% 54% −8 69% 58% −11
Treatment effect 29% 25% −4 30% 26% −4
Knee OA NSAIDs Placebo effect 27% 39% +12 26% 39% +13
Active treatment effect 52% 59% +7 51% 58% +7
Treatment effect 25% 20% −5 25% 19% −6
*See section 3 of the manuscript for detailed explanations.
**
‘Elaboration’ database is the one that permitted to propose the formal sets of responder criteria (5); ‘Revisit’ database is the one that permitted to revisit the formal sets of responder criteria
and to evaluate the simplified sets of responder criteria.
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Table III
Performances observed with each scenario in the ‘revisit’ database*: Percentage of patients improved in placebo and active treatment groups (i.e., placebo effect and active treatment effect),
treatment effect, sample size per arm required in future trials, =0.05, =0.20, two-tailed, expected placebo effect=that observed with this database, expected active treatment effect=that
observed with this database
Localization Knee OA Knee OA Hip OA Knee OA Whatever the joint Whatever the joint Whatever the joint
Drug Systemic Specific
OA Drug
IA Specific
OA Drug
NSAIDs NSAIDs NSAIDs Whatever the systemic
treatment
Whatever the treatment
Scenario A % improved in active group 38.0%** 58.4% 53.6% 59.3% 58.3% 57.2% 57.2%
% improved in placebo group 31.1%** 35.3% 28.9% 39.5% 36.8% 35.7% 35.7%
Treatment effect 6.9% 23.1% 24.7% 19.8% 21.5% 21.5% 21.5%
Sample size 745 73 62 99 84 84 84
Scenario B % improved in active group 35.8% 57.4% 58.0% 58.4% 58.7% 57.5% 57.5%
% improved in placebo group 29.0% 34.6% 31.5% 39.1% 37.4% 35.8% 35.6%
Treatment effect 6.8% 22.8% 26.5% 19.3% 21.3% 21.7% 21.9%
Sample size 743 74 55 105 86 82 81
Scenario C % improved in active group 43.7% 70.3% 60.3% 65.1% 64.7% 63.6% 63.9%
% improved in placebo group 38.0% 42.9% 34.4% 45.3% 43.3% 42.3% 42.2%
Treatment effect 5.7% 27.4% 25.9% 19.8% 21.4% 21.3% 21.7%
Sample size 1167 51 58 98 84 86 82
Scenario D % improved in active group 44.6% 70.6% 60.5% 65.4% 65.0% 63.9% 64.2%
% improved in placebo group 38.7% 43.6% 34.8% 45.9% 43.9% 42.8% 42.9%
Treatment effect 5.9% 27.0% 25.7% 19.5% 21.1% 21.1% 21.3%
Sample size 1095 52 59 101 87 87 85
Scenario E % improved in active group 47.8% 72.6% 60.5% 65.8% 65.3% 64.3% 64.7%
% improved in placebo group 45.0% 44.5% 35.2% 45.9% 44.0% 44.2% 44.3%
Treatment effect 2.8% 28.1% 25.3% 19.9% 21.3% 20.1% 20.4%
Sample size 4979 48 61 97 85 96 93
Scenario F % improved in active group 49.4% 72.9% 60.8% 66.4% 66.0% 65.1% 65.5%
% improved in placebo group 46.2% 45.2% 35.5% 46.6% 44.5% 44.8% 44.9%
Treatment effect 3.2% 27.7% 25.3% 19.8% 21.5% 20.3% 20.6%
Sample size 3824 49 61 98 83 94 91
*‘Revisit’ database is the one that permitted to revisit the formal sets of responder criteria and to evaluate the simplified sets of responder criteria.
**Percentage of patients improved in the placebo group or in the active treatment group (i.e., placebo effect and active treatment effect).
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effect was observed when using scenario E (28.1%). The
lowest sample size ‘required’ for future intra- articular
specific OA drug trials in knee OA were observed when
using the simplified scenarios (51, 52, 48 and 49 patients
per arm for scenarios C, D, E and F respectively, versus 73
and 74 patients per arm for scenarios A and B).
Performances of the six scenarios in the revisit
database whatever the drug class, the route of
administration or the localization of OA
NSAIDs whatever the OA localization. The highest active
treatment effect was observed when using scenario F
(66.0%), and at variance the lowest placebo effect was
observed when using scenario A (36.8%). The treatment
effect was similar whatever the scenario (21.5%, 21.3%,
21.4%, 21.1%, 21.3% and 21.5% for scenarios A, B, C, D,
E and F respectively). The sample size “required” for future
NSAIDs trials in OA was also similar whatever the scenario
(84, 86, 84, 87, 85 and 83 patients per arm for scenarios A,
B, C, D, E and F respectively).
Whatever the systemic drug (i.e. systemic specific OA
drugs and NSAIDs) and whatever the localization. The
highest active treatment effect was observed when using
scenario F (65.1%), and at variance the lowest placebo
effect was observed when using scenario B (21.7%). The
treatment effect was similar whatever the scenario (21.5%,
21.7%, 21.3%, 21.1%, 20.1% and 20.3% for scenarios A,
B, C, D, E and F respectively). The “required” sample size
was also similar whatever the scenario (84, 82, 86, 87, 96
and 94 patients per arm for scenarios A, B, C, D, E and F
respectively).
Whatever the drug and whatever the localization. The
highest active treatment effect was observed when using
scenario F (65.5%), and at variance the lowest placebo
effect was observed when using scenario B (35.6%). The
treatment effect was similar whatever the scenario (21.5%,
21.9%, 21.7%, 21.3%, 20.4% and 20.6% for scenarios A,
B, C, D, E and F respectively). The sample size “required”
for future trials in OA was also similar whatever the
scenario (84, 81, 82, 85, 93 and 91 patients per arm for
scenarios A, B, C, D, E and F respectively).
EXPERTS’ OPINION APPROACH RESULTS
Based on the observed results, it was considered that the
data driven approach did not permit to select a specific set
of criteria. However, at least two of these performances
(treatment effect and required sample size) were similar
whatever the scenario (A to F). These results were pre-
sented to the participants of the Osteoarthritis session
of the OMERACT VI conference (Brisbane 2002). After
discussion and voting, it appears that:
+ The treatment effect and the required sample size were
the two major characteristics to take into account in the
choice of an optimal set of criteria to be used for clinical
trials.
+ Two other characteristics were also considered as
important:
1) The definition of an improvement based not only on a
relative change but also on an absolute change
(scenarios A, C and E versus scenarios B, D and F)
2) The simplicity of the presentation: same cut-offs, set of
responder criteria whatever the localization, the study
drug and the route of administration (scenario A, B
versus C, D, E and F).
Based on this preliminary discussion between experts
and after a voting session, scenario D was selected
(Fig. 4). It is now labeled the ‘OMERACT-OARSI’ set of
responder criteria.
EVALUATION OF THE DIFFERENT SETS OF CRITERIA
Table IV summarizes the results of the procedure permit-
ting the evaluation of the different scenarios. This table
shows that the treatment effect was similar whatever the
evaluated scenario, but for hip OA, both the sensitivity
and the specificity (active treatment effect and placebo
treatment effect) were higher for the scenario D.
Discussion
This study, which combined the efforts of academic
researchers, representatives of the pharmaceutical
industry and representatives of health agency, proposes a
simplified set of responder criteria for clinical trials in OA by
simplifying the initial OARSI set of criteria using a data
driven and experts’ opinion approach. Limitations of this
study include (i) the absence of analgesics trials in our
analysis of the improvement between active drug-treated
group and placebo-treated group; (ii) Available trials con-
cerned only knee or hip OA and no other OA localization;
(iii) The collected data concerned only the core set of
criteria. Drug companies provided for each trial, the per-
centage of responders in the active treatment group and
the percentage of non-responders in the placebo group,
according to each scenario. We did not have access to the
individual data, neither to the percentage of responders for
each domain separately (pain, function, global patient’s
assessment). This lack of data did not allow us to estimate
if the core set of criteria was less powerful than each
domain treated separately, as has been done for rheuma-
toid arthritis7; (iv) The cut-offs of the simplified scenarios
were inspired by the formal ones. However, more specific
cut-offs could not be estimated due to the lack of individual
data for the 8164 OA patients.
We observed considerable variability in the results with
regard to the study population (elaboration versus revisit
database) within the formal sets of criteria. This variability
could be attributed to a variability between the patients
included in the two databases. However, in both of them,
most of the trials have been conducted in multicenter
international trials following a very similar approach con-
cerning the inclusion and exclusion criteria (phase II and
phase III trials).
In the elaboration phase of the formal OARSI set of
criteria, the loss of sensitivity and specificity using identical
cut-offs, whatever the localization and the study drug, did
not allow to propose a simple set of criteria (similar cut-off
whatever the OA localization and the study drug). The
variability of the performances of these formal sets of
criteria between the two databases was in contradiction
with the results obtained in the elaboration phase and
prompted us to further evaluate a simplification of the set of
responder criteria.
The data driven conclusions are that, whatever the OA
localization, the study drug or the route of administration,
formal scenarios A and B had the lowest placebo effect,
and scenario F had the highest active treatment effect. In
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contrast, the treatment effect and the required sample size
were quite similar whatever the scenario, ranging from
20.4% to 21.9% and from 81 to 93 patients per arm
respectively.
Although the data driven approach did not allow to select
any particular scenario, the simplification of the set of criteria
did not result in a loss of relevant performances. Indeed, a
higher active treatment effect and a higher placebo effect
were observed when using the simplified scenarios in both
databases. Conversely, the treatment effect and the sample
size required to obtain the observed placebo and active
effects were similar whatever the scenario (whether formal
or simplified) in the revisit database.
According to the experts, these two performances were
the most important for an optimal set of responder criteria.
Although all the evaluated scenarios provided similar
results for these performances, the experts’ choice was
scenario D (Fig. 4), which confirms the importance of:
1) A format that requires both an absolute change and a
relative change.
2) A format that considers both pain and function as
important domains; in certain studies, however,
changes in functional disability are at least as important
as changes in pain.
OMERACT- OARSI set of responder criteria
High improvement in pain or in function  >50%
and absolute change >20 
Improvement in at least 2 of the 3 following: 
•   pain >20% and absolute change >10 
•   function >20% and absolute change >10 
•   patient’s global assessment >20% and absolute change >10 
Þ
No
Ø
Ý
Yes
Ø
Response
Þ
No
Ø
No Response 
Ý
Yes
Ø
Response
Fig. 4. OMERACT–OARSI Set of responder criteria.
Table IV
Percentage of patients responding when the OMERACT-OARSI and formal proposition A and B criteria sets are applied to a validation data
set*
Validation database Criteria set Knee NSAID trial Hip NSAID trial
Sensitivity Specificity Sensitivity Specificity
Elaboration OMERACT-OARSI 59% 40% 72% 44%
Revisit OARSI-Proposition A 59% 39% 54% 29%
Revisit OARSI-Proposition B 58% 39% 58% 26%
*Sample size required per arm alpha=0.05, beta=0.20, two-tailed.Sensitivity=% responders on active drug (NSAIDs). 1-Specificity=%
responders on placebo.
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The observed treatment effect whatever the drug and
whatever the treatment when using scenario D is 21.3%.
This result is close to what is expected in OA, i.e., 20-
30%8,9.
The required sample size with scenario D whatever the
drug and whatever the treatment is 85 patients per arm.
This is similar to the sample size required when using the
previous formal set of criteria.
In conclusion, we propose a simplified definition for
symptomatic improvement in osteoarthritis. This set of
criteria, approved both by the OARSI and the OMERACT
committees, is at least as powerful as the previous OARSI
formal set of criteria and its simplification will probably
enhance its use in future OA trials.
Other studies are required on order to further validate
this proposed OMERACT-OARSI set of criteria in other
sets of patients suffering from osteoarthritis of different
localizations and treated differently, e.g., with analgesics or
non-pharmacological therapies.
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